Loading…

Clarivate PLCCLVTCompetitor analysis, valuation and peers

United States · USD·Industrials›Miscellaneous Commercial Services

Provider of intellectual property, scientific and academic research information, analytics and software services.

Momentum leader 88
Mkt cap
$1.50B
US dollars, full cap
Free float
52%
of shares outstanding
$/day
$8.37M
20-day average traded
Fwd P/E
3.8×
forward earnings
ROIC−WACC
-5.4 pp
WACC 7.1%
Hurdle
-1 pp
Req g minus delivered
Next earnings
116 days
2 Mar 2027
Close · USD$2.34
1D+0.4%
1W+41.8%
1M+43.6%
3M+23.8%
6M-15.8%
YTD-29.9%
1Y-32.8%
ATR %6.7%
Beta0.56
52w lowhigh39.5% off high

What Clarivate does

Provider of intellectual property, scientific and academic research information, analytics and software services.

Earns most of its income from annual subscriptions to databases and software that customers use every day, so revenue is recurring and tied to renewal rates; trademark and patent filing services add transaction-based income. It was carved out of Thomson Reuters in 2016 and has grown by acquisition.

Products and services

  • IP/patent search & analytics (CompuMark, Derwent)
  • Scientific/academic research analytics (Web of Science)
  • Life sciences/regulatory intelligence software

Customers

  • Law firms/corporate IP departments
  • Academic institutions/researchers
  • Pharmaceutical companies

Where it sits in the supply chain

  • Business services/information
  • IP & scientific information services
  • Patent/IP data, academic research…

What could go right

  • IP filing volume growth (especially China/emerging markets)
  • Academic research analytics demand

What could go wrong

  • High leverage/debt load post-acquisitions
  • Integration risk from multiple large M&A deals

Moat: narrow (data, switching costs, brand). Proprietary, decades-deep IP and citation databases are difficult and costly for rivals to replicate.

Headquarters: London, United Kingdom · Founded: 2016 · Employees: 12,000

Named competitors

Clarivate at a glance

Size Clarivate (CLVT) is a United States Industrials company (Miscellaneous Commercial Services) with a market value of $1.50B, the 1992nd largest of 3,117 United States companies the cockpit tracks. Shares closed at $2.34 on 6 Nov 2026.

Performance Over six months the shares fell 15.8%, against -6.0% for the median peer and -1.1% for the United States market (cap-weighted) — 7th lowest of 21 in its peer set.

Growth Revenue fell 9.2% over the last twelve months (peer median +4.5%); the operating margin is 7.9% (peer median 10.6%).

Valuation It trades at 3.8× forward earnings against a peer median of 19.4× (cheapest of 18).

Price implies For today's price to make sense, revenue must grow about 13% a year for seven years (Req g). Recent delivered growth is +14%, so the hurdle is -1 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 5.4 points below its cost of capital (7.1% WACC).

Short interest Short interest is 7.3% of the free float (15 Oct 2026).

Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).

Relative performance

608010011 May 202611 Aug 20266 Nov 2026Peer median 94CLVT 84
Six months, rebased to 100: Clarivate against the median of its 20 peers (local-currency closes).

Clarivate financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$2.27B$2.46B$2.56B$2.63B$2.66B
Revenue growth—-4%-3%-1%—
Gross profit$829M$864M$960M$1.01B$995M
EBITDA$901M$936M$960M$983M$976M
Net income-$386M-$201M-$637M-$911M-$3.96B
Free cash flow$322M$365M$337M$502M$304M
Capital expenditure$237M$263M$289M$242M$203M
Total debt$4.18B$4.48B$4.59B$4.81B$5.10B

Quarterly statements and history in the cockpit →

Clarivate competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-25%0%+25%2258AFRY6006623014139917688202MOL688800603406AWX002607ICFI9744DBG688128ECLERX688112CONCORDBIO300725688757CLVT6-month return →1-month return →
Up and to the right = strong over both horizons. Clarivate is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%0×200×400×AFRY6006623014139917688202MOLAWX002607ICFI688128ECLERX688112CONCORDBIO300725CLVTRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Clarivate is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%-25%0%25%50%AFRY6006629917MOL688800603406AWX002607688128ECLERX688112CONCORDBIO300725CLVTGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Clarivate is the large dot.

Clarivate competitors and peer comparison

Head to head with its named competitors (CLVT vs REL.L vs TRI.TO)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Clarivate CLVT$1.50B-16%-9%8%3.8×13.4%
Relx REL.L$70.4B+23%+2%32%21.3×1.8%
Thomson Reuters TRI.TO$49.1B+25%+6%26%24.8×2.7%

How Clarivate compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Clarivate against its 20 peers (data as of 6 Nov 2026)
MeasureCLVTPeer medianRank in peer set
1-month return+43.6%-8.2%2nd highest of 21
6-month return-15.8%-6.0%7th lowest of 21
Distance from 52-week high-39.5%-36.0%8th lowest of 21
Revenue growth (TTM)-9.2%+4.5%2nd lowest of 21
Operating margin7.9%10.6%8th lowest of 21
Forward P/E3.8×19.4×cheapest of 18
Growth the price implies (Req g, 7 yrs)13.4%9.1%8th most demanding of 17
Growth delivered (Del g)+14.4%+9.0%5th highest of 17
Hurdle (Req g minus delivered)-0.9 pp-5.4 pp7th most demanding of 17
ROIC minus cost of capital-5.4 pp+0.9 pp5th lowest of 19
EV / EBITDA6.0×9.7×2nd cheapest of 9
Net debt / EBITDA4.4×1.2×most indebted of 9

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Clarivate CLVTUnited States$1.50B-16%-9%8%3.8×13.4%+14.4%
Foxtron Vehicle Technologies 2258.TWTaiwan$1.50B+1%-50%-132%n/an/an/a
AFRY AFRY.STSweden$1.50B+17%-4%7%12.7×-2.2%+6.3%
Shanghai Foreign Service 600662.SSChina$1.49B-14%+1%2%13.8×-20.6%+1.9%
Shenzhen Ampron Technology 301413.SZChina$1.48B-7%+11%2%423.6×n/an/a
Taiwan Secom 9917.TWTaiwan$1.47B-8%+3%16%14.2×-2.3%+6.7%
Shanghai Medicilon 688202.SSChina$1.47B+18%+42%-2%91.8×n/an/a
Moltiply MOL.MIItaly$1.53B+6%+32%15%14.6×10.8%+21.0%
Suzhou Recodeal Interconnect System 688800.SSChina$1.47B-55%+5%9%28.7×26.1%+38.9%
Yangzhou Tinfulong 603406.SSChina$1.53B-25%-4%12%n/a7.5%+10.6%
AEM AWX.SISingapore$1.55B-18%+15%11%23.4×15.4%-5.1%
Offcn Education Technology 002607.SZChina$1.56B-36%-2%13%38.8×17.7%-27.6%
ICF International ICFIUnited States$1.43B+14%-8%8%10.8×-2.2%+4.4%
MEITEC 9744.TJapan$1.57B+3%+2%14%18.7×-4.6%+7.3%
Derichebourg DBG.PAFrance$1.42B-24%-3%5%8.9×6.8%+6.3%
China National Electric Apparatus Research Institute 688128.SSChina$1.42B-12%+8%11%15.5×4.0%+13.5%
eClerx Services ECLERX.NSIndia$1.59B0%+22%20%19.4×17.2%+21.4%
Siglent Technologies 688112.SSChina$1.41B-5%+30%24%46.2×31.3%+22.0%
Concord Biotech CONCORDBIO.NSIndia$1.40B+2%+4%28%38.2×47.1%+11.6%
PharmaBlock Sciences (Nanjing) 300725.SZChina$1.61B+16%+11%11%44.6×27.8%+14.1%
Wintech Nano (Suzhou) 688757.SSChina$1.39B-18%+23%7%n/an/an/a

Questions

Who are Clarivate's main competitors?
Named competitors: RELX (REL.L), Thomson Reuters (TRI.TO). The cockpit's measured peer set (industry) also includes Foxtron Vehicle Technologies (2258.TW), AFRY (AFRY.ST), Shanghai Foreign Service (600662.SS), Shenzhen Ampron Technology (301413.SZ), Taiwan Secom (9917.TW), Shanghai Medicilon (688202.SS).
Is Clarivate expensive compared with its peers?
On forward p/e it trades at 3.8× against a peer median of 19.4×, cheapest of 18 in its peer set. For today's price to make sense, revenue must grow about 13% a year for seven years (Req g). Recent delivered growth is +14%, so the hurdle is -1 pp: the price already allows for a slowdown.
How has Clarivate stock performed?
Over six months to 6 Nov 2026 the shares returned -15.8% against -6.0% for the median peer; over one year -32.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.